CSCIFOTCPerfumes, Cosmetics & Other Toilet PreparationsFiscal year ends December 31
COSCIENS Biopharma Inc.
Financials through Q1 FY2026, quarter ended Mar 31, 2026Last filing: 20-F on Mar 25, 2026
$6.49+0.00 (0.00%)
Close on Oct 19, 2026
- Market cap
- $24.10M
- P/E (TTM)
- –
- Dividend yield
- –
COSCIENS Biopharma Inc. revenue by segment
By business segment
| Revenue | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Active ingredient [member] | $7.04M | $8.49M | $7.14M | $14.57M | – | – | – | – | – | – | 93.9% | -17.1% |
| Biopharmaceutical [member] | $461.00K | $1.10M | – | – | – | – | – | – | – | – | 6.1% | -57.9% |
| Denmark [member] | – | – | $11.00K | $160.00K | $185.00K | $2.66M | $413.00K | – | – | – | – | – |
| Other [member] | – | – | $48.00K | $3.00K | – | $19.00K | $45.00K | – | – | – | – | – |
| Ireland [member] | – | – | $122.00K | $82.00K | – | $73.00K | $74.00K | – | – | – | – | – |
| Switzerland [member] | – | – | $4.32M | $5.40M | $5.08M | $905.00K | – | – | – | – | – | – |
| Pharmaceutical [member] | – | $1.10M | – | – | – | – | – | – | – | – | – | – |
By product or service
| Revenue | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Active ingredients [member] | $7.04M | $8.49M | $7.14M | $14.57M | – | – | – | – | – | – | 93.9% | -17.1% |
| Biopharmaceutical [member] | $461.00K | $1.10M | – | – | – | – | – | – | – | – | 6.1% | -57.9% |
| Royalties Strongbridge Agreement [Member] | – | – | – | – | – | $56.00K | $45.00K | – | – | – | – | – |
| Novo Supply Agreements [Member] | – | – | – | – | $185.00K | $304.00K | $284.00K | – | – | – | – | – |
| License Strongbridge Agreement [Member] | – | – | – | – | – | $68.00K | $74.00K | – | – | – | – | – |
| Novo Supply Agreement [Member] | – | – | – | – | – | $2.37M | $129.00K | – | – | – | – | – |
| Royalties Novo Amendement [Member] | – | – | – | – | $68.00K | $11.00K | – | – | – | – | – | – |
| License Novo Amendment [Member] | – | – | – | – | $1.67M | $843.00K | – | – | – | – | – | – |
| License fees [member] | – | – | – | $1.70M | $1.67M | $911.00K | – | – | – | – | – | – |
| Product sales [member] | – | – | – | $57.00K | – | $2.37M | – | – | – | – | – | – |
| Royalties [member] | – | – | – | $101.00K | $68.00K | $67.00K | – | – | – | – | – | – |
| Supply chain [member] | – | – | – | $161.00K | $185.00K | $304.00K | – | – | – | – | – | – |
| Development Services Novo Amendment [Member] | – | – | – | – | $3.34M | – | – | – | – | – | – | – |
| Development services [member] | – | – | – | $3.62M | $3.34M | – | – | – | – | – | – | – |
By region
| Revenue | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| United states [member] | $4.60M | $6.69M | $3.42M | $8.60M | – | – | – | – | – | – | 61.4% | -31.2% |
| Germany [member] | $2.38M | $1.36M | $3.56M | $4.56M | – | – | – | – | – | – | 31.7% | +74.9% |
| United kingdom [member] | $457.00K | $976.00K | – | – | – | – | – | – | – | – | 6.1% | -53.2% |
| Other [member] | $59.00K | $260.00K | $164.00K | $83.00K | – | $19.00K | $45.00K | – | $3.00K | – | 0.8% | -77.3% |
| United States [Member] | – | – | – | – | – | – | – | $1.42M | $452.00K | $410.00K | – | – |
| Other | – | – | – | – | – | – | – | $0 | $3.00K | $51.00K | – | – |
| China | – | – | – | – | – | – | – | $275.00K | $262.00K | $249.00K | – | – |
| Ireland | – | – | – | – | – | $73.00K | $74.00K | $24.91M | $0 | $0 | – | – |
| Singapore | – | – | – | – | – | – | – | $0 | $0 | $101.00K | – | – |
| British Virgin Islands | – | – | – | – | – | – | – | $280.00K | $206.00K | $100.00K | – | – |
| United States [member] | – | – | – | – | – | – | – | $1.42M | $452.00K | – | – | – |
| China [Member] | – | – | – | – | – | – | – | $275.00K | $262.00K | – | – | – |
| British Virgin Islands [Member] | – | – | – | – | – | – | – | $280.00K | $206.00K | – | – | – |
| Ireland [member] | – | – | – | – | – | – | $74.00K | $24.91M | – | – | – | – |
| Denmark [member] | – | – | – | – | – | – | $413.00K | – | – | – | – | – |
| Denmark | – | – | – | – | – | $2.66M | $413.00K | – | – | – | – | – |
| Switzerland | – | – | – | – | – | $905.00K | – | – | – | – | – | – |
| China [member] | – | – | – | $1.33M | – | – | – | – | – | – | – | – |
| Columbia [member] | – | $300.00K | – | – | – | – | – | – | – | – | – | – |
From the segment and revenue-disaggregation notes of COSCIENS Biopharma's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.